Finding signs that predict response to stapokibart in nasal polyps
Seeks markers of stapokibart response in people with nasal polyps.
Key facts
- Who runs it
- Beijing Tongren Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 90 people, planned
- Started
- 1 Feb 2025
- Planned end
- 1 Jul 2026
- Type of study
- Interventional
- Treatments tested
- Stapokibart
- Mometasone Furoate Nasal Spray (MFNS)
- Record updated
- 6 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic sinus inflammation and nasal polyps in both sides of the nose. All take stapokibart plus mometasone nasal spray, to find markers that predict response.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Chronic rhinosinusitis with nasal polyps on both sides. Nasal Polyp Score ≥4 (at least 2 per side) and nasal congestion score ≥2. Blocked nose plus loss of smell or runny nose for at least 4 weeks.
- Earlier treatment
- Must have had steroid pills or injections within 2 years, or be unable to take them, and/or polyp surgery more than 6 months before screening. Must have used a steroid nose spray at a stable dose for at least 4 weeks.
Main reasons for not taking part
- Recent biologic treatment (within 10 weeks or 5 half-lives, whichever is longer)
- Immune-suppressing medicines within 8 weeks or 5 half-lives, or newly started leukotriene blockers, oral steroids or traditional Chinese medicine within 4 weeks
- Nose surgery that changed the nose so polyps cannot be scored
- Lung test FEV1 ≤50% of predicted normal
- Pregnant, breastfeeding or planning either; allergy to MFNS, anti-IL-4R antibodies or stapokibart; other poorly controlled serious diseases
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age 18-75 years old
- With bilateral chronic rhinosinusitis with nasal polyposis
- Nasal Polyp Score ≥4 (minimum score of 2 per nasal cavity) at baseline
- Nasal congestion score ≥2 at baseline
- Patients who have received systemic corticosteroids (SCS) treatment within 2 years before screening, and/or have contraindications or intolerance to SCS treatment, and/or received surgical for nasal polyps more than 6 months before screening
- Have been using intranasal corticosteroids (INCS) at a stable dose for at least 4 weeks before screening
- Symptoms of nasal obstruction and additional symptoms such as loss of smell or rhinorrhea should be present for at least 4 weeks before screening
- Good adherence
Who cannot take part
- Not enough washing out period for prior biological therapy (within 10 weeks or 5 half-lives [whichever is longer] before baseline)
- Initiation of leukotriene receptor antagonist treatment, oral glucocorticoid treatment, or traditional Chinese medicine treatment for chronic rhinosinusitis within 4 weeks before baseline
- Subjects who have undergone surgery that changed the nasal structure and cannot be evaluated for Nasal Polyp Score
- Concomitant with other poorly controlled serious diseases or recurrent chronic diseases
- Use of systemic immunosuppressants for inflammatory diseases or autoimmune diseases within 8 weeks or 5 half-lives before baseline (whichever is longer)
- Hypersensitivity to MFNS or anti-IL-4R monoclonal antibodies or stapokibart components
- Participants with a forced expiratory volume in 1 second (FEV1) ≤50% of predicted normal during screening/run-in period
- Women who are pregnant, breastfeeding, or planning either during the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments. This clinical trial aims to develop a non-invasive predictive model to help determine how effective IL-4Rα targeted monoclonal antibody therapy will be for individuals with CRSwNP.
The group in the trial
- therapy groupTreatment being tested
Stapokibart subcutaneously every two weeks plus mometasone furoate nasal spray 200 μg once daily
Treatment: Stapokibart and Mometasone Furoate Nasal Spray (MFNS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
- Plain-language title
- Finding signs that predict response to stapokibart in nasal polypsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06801353, who can take part
- Record updated
- 6 February 2025